CL2015000115A1 - Uso de inhibidores de vegfr-3 para tratar el carcinoma hepatocelular. - Google Patents

Uso de inhibidores de vegfr-3 para tratar el carcinoma hepatocelular.

Info

Publication number
CL2015000115A1
CL2015000115A1 CL2015000115A CL2015000115A CL2015000115A1 CL 2015000115 A1 CL2015000115 A1 CL 2015000115A1 CL 2015000115 A CL2015000115 A CL 2015000115A CL 2015000115 A CL2015000115 A CL 2015000115A CL 2015000115 A1 CL2015000115 A1 CL 2015000115A1
Authority
CL
Chile
Prior art keywords
vegfr
inhibitors
hepatocellular carcinoma
treat hepatocellular
treat
Prior art date
Application number
CL2015000115A
Other languages
English (en)
Inventor
Antoine Alam
Isabelle Blanc
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2015000115A1 publication Critical patent/CL2015000115A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015000115A 2012-07-17 2015-01-15 Uso de inhibidores de vegfr-3 para tratar el carcinoma hepatocelular. CL2015000115A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672489P 2012-07-17 2012-07-17
EP12305866 2012-07-17

Publications (1)

Publication Number Publication Date
CL2015000115A1 true CL2015000115A1 (es) 2015-05-04

Family

ID=49948312

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000115A CL2015000115A1 (es) 2012-07-17 2015-01-15 Uso de inhibidores de vegfr-3 para tratar el carcinoma hepatocelular.

Country Status (31)

Country Link
US (1) US9376432B2 (es)
EP (1) EP2874625B1 (es)
JP (1) JP6226981B2 (es)
KR (1) KR102068860B1 (es)
CN (1) CN104602691B (es)
AU (1) AU2013292054B2 (es)
BR (1) BR112015000942A2 (es)
CA (1) CA2878987C (es)
CL (1) CL2015000115A1 (es)
CR (1) CR20150029A (es)
CY (1) CY1119415T1 (es)
DK (1) DK2874625T3 (es)
EA (1) EA027982B1 (es)
ES (1) ES2635105T3 (es)
HK (1) HK1206257A1 (es)
HR (1) HRP20171227T1 (es)
HU (1) HUE035712T2 (es)
IL (1) IL236718A (es)
LT (1) LT2874625T (es)
MA (1) MA37821A1 (es)
MX (1) MX367402B (es)
PH (1) PH12015500094A1 (es)
PL (1) PL2874625T3 (es)
PT (1) PT2874625T (es)
RS (1) RS56178B1 (es)
SG (1) SG11201500156SA (es)
SI (1) SI2874625T1 (es)
TN (1) TN2015000021A1 (es)
TW (1) TW201406759A (es)
WO (1) WO2014012942A1 (es)
ZA (1) ZA201500182B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
CN104736533B (zh) 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
HK1209104A1 (en) 2012-08-17 2016-03-24 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760456B1 (fr) * 1997-03-05 2000-05-12 Sanofi Sa Procede de preparation de derives de 2-thienyl-ethylamine
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
CN1191252C (zh) * 2003-08-11 2005-03-02 中国药科大学 3-位取代的喹诺酮衍生物及其在药学上的应用
US20050209247A1 (en) * 2003-11-07 2005-09-22 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
CN1325494C (zh) * 2005-08-18 2007-07-11 中国药科大学 3-位取代的萘啶酮类化合物及其制备方法和在制药中的应用
KR100744826B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 이미다졸기가 치환된 퀴놀리논 유도체
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2009053799A1 (en) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2933701A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
WO2010073078A2 (en) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

Also Published As

Publication number Publication date
JP6226981B2 (ja) 2017-11-08
AU2013292054A1 (en) 2015-02-05
SI2874625T1 (sl) 2017-10-30
MX367402B (es) 2019-08-20
HUE035712T2 (en) 2018-05-28
HRP20171227T1 (hr) 2017-10-20
DK2874625T3 (en) 2017-09-11
EA027982B1 (ru) 2017-09-29
TN2015000021A1 (en) 2016-06-29
CN104602691A (zh) 2015-05-06
CR20150029A (es) 2015-04-06
EP2874625A1 (en) 2015-05-27
KR20150036401A (ko) 2015-04-07
IL236718A0 (en) 2015-02-26
CA2878987A1 (en) 2014-01-23
JP2015522598A (ja) 2015-08-06
SG11201500156SA (en) 2015-02-27
PH12015500094A1 (en) 2015-03-02
RS56178B1 (sr) 2017-11-30
LT2874625T (lt) 2017-08-25
TW201406759A (zh) 2014-02-16
HK1206257A1 (en) 2016-01-08
AU2013292054B2 (en) 2017-08-03
WO2014012942A1 (en) 2014-01-23
IL236718A (en) 2017-11-30
US9376432B2 (en) 2016-06-28
ZA201500182B (en) 2015-12-23
EP2874625B1 (en) 2017-05-17
MA37821A1 (fr) 2018-02-28
PL2874625T3 (pl) 2017-10-31
US20150183780A1 (en) 2015-07-02
CN104602691B (zh) 2016-12-28
EA201590229A1 (ru) 2015-05-29
CA2878987C (en) 2020-07-21
KR102068860B1 (ko) 2020-01-21
ES2635105T3 (es) 2017-10-02
BR112015000942A2 (pt) 2017-06-27
CY1119415T1 (el) 2018-03-07
MX2015000797A (es) 2015-08-13
PT2874625T (pt) 2017-08-16

Similar Documents

Publication Publication Date Title
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
LT4275756T (lt) Bipirazolo dariniai kaip jak inhibitoriai
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
LT2841428T (lt) Dnr-pk inhibitoriai
DK3628670T3 (da) Saltform til ezh2-hæmning
LT2885010T (lt) Tautopatijos gydymo būdai
LT2959005T (lt) Medicininis naudojimas, susijęs su telomerų ilgėjimu
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
DK2981526T3 (da) Naphthylureaderivater til anvendelse som kinaseinhibitorer
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
BR112015009121A2 (pt) métodos para produzir 5-(halometil)furfural
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
BR302012004026S1 (pt) Configuração aplicada em acessório para liquidificador.
HUE051648T2 (hu) CCR3-gátlók használata
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
EP3632467C0 (en) COMPLEMENT FACTOR H INHIBITORS
CO6801728A2 (es) Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis
EP2858975A4 (en) FBXO3 INHIBITORS
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
DK2879664T3 (da) Transdermal formulering indeholdende cox-inhibitorer
CL2015000115A1 (es) Uso de inhibidores de vegfr-3 para tratar el carcinoma hepatocelular.
CO6880061A2 (es) Método para tratar el cáncer mediante el uso combinado de fármacos
HUE060237T2 (hu) Szedoheptulóz alkalmazása gyulladás megelõzésére vagy kezelésére
PL2617412T3 (pl) Kompozycja do leczenia miejscowego
FR2997080B1 (fr) Inhibiteurs de neprilysine